Published in Br J Psychiatry on April 01, 2009
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet (2012) 0.89
Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatr Dis Treat (2010) 0.87
Brain-derived neurotrophic factor in chronic periodontitis. Mediators Inflamm (2014) 0.78
Investigation of the genetic interaction between BDNF and DRD3 genes in suicidical behaviour in psychiatric disorders. World J Biol Psychiatry (2014) 0.75
BDNF Val66Met polymorphism and the affective component. Br J Psychiatry (2009) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet (2003) 26.59
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science (2006) 9.31
A neurotrophic model for stress-related mood disorders. Biol Psychiatry (2006) 8.97
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet (1998) 8.02
Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med (2008) 4.58
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry (2002) 3.95
Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull (2005) 3.93
Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry (2002) 3.78
Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci (2005) 3.17
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry (2007) 2.70
Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry (2005) 2.58
What can genome-wide association studies tell us about the genetics of common disease? PLoS Genet (2008) 2.35
Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry (2005) 2.29
Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry (2006) 2.16
Reflections on the relationship between psychiatric genetics and psychiatric nosology. Am J Psychiatry (2006) 2.16
Beyond the Kraepelinian dichotomy: acute and transient psychotic disorders and the necessity for clinical differentiation. Br J Psychiatry (2006) 2.15
The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet (2002) 1.98
Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest (2007) 1.74
Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry (2006) 1.71
Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry (2005) 1.61
Differential regulation of brain-derived neurotrophic factor transcripts during the consolidation of fear learning. Learn Mem (2004) 1.53
The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging (2005) 1.49
Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry (2005) 1.48
A comparison of the utility of dimensional and categorical representations of psychosis. UK700 Group. Psychol Med (1999) 1.47
Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet (2006) 1.37
Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am J Psychiatry (2004) 1.34
Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry (2005) 1.26
Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet (2008) 1.24
BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry (2005) 1.22
Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch Gen Psychiatry (2006) 1.19
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res (2006) 1.18
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct (2005) 1.14
Brain-derived neurotrophic factor variants are associated with childhood-onset mood disorder: confirmation in a Hungarian sample. Mol Psychiatry (2005) 1.07
The acute schizoaffective psychoses. 1933. Am J Psychiatry (1994) 1.00
Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet (2005) 0.99
Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet (2007) 0.99
Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry (2006) 0.96
Neurotrophic factors in the central nucleus of amygdala may be organized to provide substrates for associative learning. Brain Res (2006) 0.89
Size matters: the unexpected challenge of detecting linkage in large cohorts. Am J Psychiatry (2007) 0.85
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol (2007) 2.99
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
What does the PANSS mean? Schizophr Res (2005) 2.86
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
Genetic variation in human NPY expression affects stress response and emotion. Nature (2008) 2.65
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry (2010) 2.57
Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry (2013) 2.50
Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry (2005) 2.38
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry (2004) 2.12
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull (2008) 1.93
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord (2010) 1.90
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biol Psychiatry (2005) 1.80
Tardive dyskinesia circa 2006. Am J Psychiatry (2006) 1.78
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry (2013) 1.76
BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology (2005) 1.74
Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol (2010) 1.72
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry (2007) 1.67
Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology (2006) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res (2006) 1.65
Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci (2010) 1.61
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry (2006) 1.57
Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron (2011) 1.57
Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res (2012) 1.56
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res (2010) 1.55
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
Sudden deaths in psychiatric patients. J Clin Psychiatry (2011) 1.53
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry (2005) 1.49
Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry (2003) 1.49
A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neurosci Biobehav Rev (2009) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res (2007) 1.47
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol (2008) 1.46
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry (2007) 1.45
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res (2008) 1.45
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? J Clin Psychiatry (2011) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord (2010) 1.41
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis (2006) 1.38
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34